Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) Return on Sales (2021 - 2025)

Historic Return on Sales for InMed Pharmaceuticals (INM) over the last 5 years, with Q4 2025 value amounting to 2.47%.

  • InMed Pharmaceuticals' Return on Sales fell 1600.0% to 2.47% in Q4 2025 from the same period last year, while for Dec 2025 it was 1.7%, marking a year-over-year decrease of 600.0%. This contributed to the annual value of 1.65% for FY2025, which is 200.0% up from last year.
  • According to the latest figures from Q4 2025, InMed Pharmaceuticals' Return on Sales is 2.47%, which was down 1600.0% from 1.54% recorded in Q3 2025.
  • In the past 5 years, InMed Pharmaceuticals' Return on Sales registered a high of 0.15% during Q2 2023, and its lowest value of 16.16% during Q4 2021.
  • Its 5-year average for Return on Sales is 4.58%, with a median of 1.93% in 2023.
  • Its Return on Sales has fluctuated over the past 5 years, first surged by 151400bps in 2023, then tumbled by -13600bps in 2024.
  • InMed Pharmaceuticals' Return on Sales (Quarter) stood at 16.16% in 2021, then surged by 72bps to 4.47% in 2022, then soared by 73bps to 1.19% in 2023, then tumbled by -94bps to 2.32% in 2024, then dropped by -7bps to 2.47% in 2025.
  • Its last three reported values are 2.47% in Q4 2025, 1.54% for Q3 2025, and 1.37% during Q2 2025.